Ascendis Pharma A/S (ASND)
NASDAQ: ASND · Real-Time Price · USD
193.91
+0.90 (0.47%)
At close: Aug 28, 2025, 4:00 PM
193.90
-0.01 (-0.01%)
After-hours: Aug 28, 2025, 4:31 PM EDT
Ascendis Pharma Employees
Ascendis Pharma had 1,017 employees as of December 31, 2024. The number of employees increased by 138 or 15.70% compared to the previous year.
Employees
1,017
Change (1Y)
138
Growth (1Y)
15.70%
Revenue / Employee
$566,698
Profits / Employee
-$313,116
Market Cap
11.74B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 1,017 | 138 | 15.70% |
Dec 31, 2023 | 879 | 82 | 10.29% |
Dec 31, 2022 | 797 | 158 | 24.73% |
Dec 31, 2021 | 639 | 157 | 32.57% |
Dec 31, 2020 | 482 | 152 | 46.06% |
Dec 31, 2019 | 330 | 114 | 52.78% |
Dec 31, 2018 | 216 | 79 | 57.66% |
Dec 31, 2017 | 137 | 36 | 35.64% |
Dec 31, 2016 | 101 | 23 | 29.49% |
Dec 31, 2015 | 78 | 23 | 41.82% |
Dec 31, 2014 | 55 | 10 | 22.22% |
Dec 31, 2013 | 45 | 7 | 18.42% |
Dec 31, 2012 | 38 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
ASND News
- 1 hour ago - Ascendis Pharma to Participate in the 2025 Wells Fargo Healthcare Conference - GlobeNewsWire
- 19 days ago - Ascendis Pharma A/S (ASND) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 21 days ago - Ascendis Pharma Reports Second Quarter 2025 Financial Results - GlobeNewsWire
- 4 weeks ago - Ascendis Pharma to Report Second Quarter 2025 Financial Results and Provide Business Update on August 7, 2025 - GlobeNewsWire
- 4 weeks ago - FDA Approves SKYTROFA® (Lonapegsomatropin-tcgd) for the Once-Weekly Treatment of Adults with Growth Hormone Deficiency - GlobeNewsWire
- 6 weeks ago - New 3-Year Phase 3 Data Confirmed Sustained Response to TransCon® PTH (Palopegteriparatide) Therapy in Adults with Hypoparathyroidism, Including Improvements in Biochemistries, Kidney Function, and Quality of Life - GlobeNewsWire
- 7 weeks ago - Ascendis to Share Its Latest Endocrinology Rare Disease Data at ENDO 2025 - GlobeNewsWire
- 2 months ago - TransCon® hGH Boosted Treatment Benefits of TransCon® CNP in Children with Achondroplasia at Week 26 Interim Analysis of the Phase 2 COACH Trial - GlobeNewsWire